-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 5, Shuanglu Pharmaceutical issued an announcement stating that it had recently received the "Drug Clinical Trial Approval Notice" (notice number : 2021LP01795, 2021LP01796), agreed to carry out clinical trials for type 2 diabetes indications
Long-acting recombinant human glucagon-like peptide-1 injection is a glucagon-like peptide (GLP-1) receptor agonist, which can effectively treat type 2 diabetes
In February 2019, Eli Lilly’s weekly preparation of GLP-1 receptor agonist dulaglutide (Duyida®) was approved to enter the domestic market